China Thymosin a1 Market Report, 2018-2022: Market Size, Competition Pattern, Prices & Prospects of the Market

DUBLIN, Jan. 7, 2019 /PRNewswire/ --

The "Investigation Report on Chinese Thymosin a1 Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Thymosins can enhance body immunity and are mainly used for the treatment of hepatitis and tumors. Thymosins mainly include Thymosin, Thymopentin and Thymosin 1. Thymosin 1 is a high-end thymosin.

It was first launched in the U.S. as an immunomodulator for tumor immunotherapy. Now it has been clinically used in the treatment of many tumors. Research shows that the use of Thymosin 1 in tumor chemotherapy and radiotherapy can enhance patients' immunity, reduce toxic side effects and infection rate, improve patients' life quality, and increase remission rate and even survival rate.

As a vaccine adjuvant, Thymosin 1 can enhance the immune response to viral vaccines such as influenza and hepatitis B vaccines for people with impaired or inhibited immune functions including patients who are receiving chronic hemodialysis and suffering from geriatric diseases.

According to the report, Thymosin 1 has been growing since it entered China, with its sales value increasing from less than CNY 7 million in 2015 to more than CNY 1.2 billion in 2017. The Chinese Thymosin 1 market is now dominated by the products of Patheon, Hainan Shuangcheng Pharmaceuticals Co., Ltd., Chengdu DIAO Jiuhong Pharmaceutical Factory, etc.

By sales value, Patheon captured more than half of the market, becoming the most powerful market player in 2017. By sales volume, Chengdu DIAO Jiuhong Pharmaceutical Factory took up the largest market share. Many domestic enterprises seek to scrabble for market shares from Patheon by the advantage of low prices.

According to the researcher, the incidence of cancer is increasing with economic development, aggravating environmental pollution and residents' changing lifestyle. Therefore, the Thymosin 1 market will continue to grow from 2018 to 2022 as the immunomodulator market grows gradually.

Topics Covered:

• Size of Chinese Thymosin 1 market
• Competition pattern of the Chinese Thymosin 1 market
• Prices in the Chinese Thymosin 1 market
• Prospects of the Chinese Thymosin 1 market

Key Topics Covered:

1 Relevant Concepts of Thymosin 1
1.1 Indications for Thymosin 1
1.2 Development History of Thymosin 1 in China
1.3 Production Permit of Thymosin 1 in China

2 Investigation on Sales of Thymosin 1 in China, 2013-2017
2.1 Sales Value of Thymosin 1 in China, 2013-2017
2.1.1 Overall Sales Value
2.1.2 Sales Value in Key Regions of China
2.2 Sales Volume of Thymosin 1 in China, 2013-2017
2.2.1 Overall Sales Volume
2.2.2 Sales Volume in Key Regions of China
2.3 Dosage Forms of Thymosin 1 in China

3 Market Shares of Major Thymosin 1 Manufacturers in China
3.1 Market Shares of Major Thymosin 1 Manufacturers
3.1.1 Market Shares by Sales Value
3.1.2 Market Shares by Sales Volume
3.2 Patheon N.V.
3.3 Chengdu DIAO Jiuhong Pharmaceutical Factory
3.3.1 Profile of Chengdu DIAO Jiuhong Pharmaceutical Factory
3.3.2 Sales of Chengdu DIAO Jiuhong Pharmaceutical Factory's Thymosin 1
(The structures of 3.4-3.9 are similar with that of 3.3.)
3.4 Hainan Shuangcheng Pharmaceuticals Co., Ltd.
3.5 Hainan Zhonghe Pharmaceutical Co., Ltd.
3.6 SPH No. 1 Biochemical & Pharmaceutical Co., Ltd.
3.7 Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd.
3.8 Chengdu Shengnuo Biopharm Co., Ltd.
3.9 Harbin Pharmaceutical Group Bio-Engineering Co., Ltd.

4 Prices of Thymosin 1 in China, 2017-2018
4.1 Analysis on Average Price of Thymosin 1 in China
4.2 Prices of Thymosin 1 of Major Enterprises
4.2.1 Patheon (Trade Name: Zadaxin)
4.2.2 Chengdu DIAO Jiuhong Pharmaceutical Factory (Trade Name: Maipuxin)
4.2.3 Hainan Shuangcheng Pharmaceuticals Co., Ltd. (Trade Name: Jitai)
4.2.4 Hainan Zhonghe Pharmaceutical Co., Ltd. (Trade Name: Heri)
4.2.5 SPH No. 1 Biochemical & Pharmaceutical Co., Ltd. (Trade Name: Xingtuokang)
4.2.6 Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical Co., Ltd. (Trade Name: Liding)
4.2.7 Chengdu Shengnuo Biopharm Co., Ltd. (Trade Name: Xinnuoli)
4.2.8 Harbin Pharmaceutical Group Bio-Engineering Co., Ltd. (Trade Name: Tailuoting)

5 Prospects of Chinese Thymosin 1 Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Competition Pattern

For more information about this report visit https://www.researchandmarkets.com/research/qwpcwc/china_thymosin_a1?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com